ANI Pharmaceuticals ANIP Other intangible assets—net
Other intangible assets—net at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's other intangible assets—net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's other intangible assets—net?
- ANI Pharmaceuticals (ANIP) reported other intangible assets—net of $467.16M in Q1 2026.
- How has ANI Pharmaceuticals's other intangible assets—net changed year-over-year?
- ANI Pharmaceuticals's other intangible assets—net decreased by 13.2% year-over-year, from $538.5M to $467.16M.
- What is the long-term trend for ANI Pharmaceuticals's other intangible assets—net?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's other intangible assets—net has grown at a 20.5% compound annual growth rate (CAGR), from $188.51M to $479.53M.
- What does other intangible assets—net mean?
- This represents the net book value of identifiable non-physical assets such as patents, intellectual property, software licenses, and trademarks, excluding goodwill. These assets are vital for companies relying on proprietary technology and R&D. It captures the value of the company's competitive moat derived from its intellectual property portfolio.